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Abstract
Duchenne muscular dystrophy (DMD) is a fatal genetic disease caused by an absence of
the 427kD muscle-specific dystrophin isoform. Utrophin is the autosomal homolog of dystro-
phin and when overexpressed, can compensate for the absence of dystrophin and rescue
the dystrophic phenotype of the mdx mouse model of DMD. Utrophin is subject to miRNA
mediated repression by several miRNAs including let-7c. Inhibition of utrophin: let-7c inter-
action is predicted to ’repress the repression’ and increase utrophin expression. We devel-
oped and tested the ability of an oligonucleotide, composed of 2’-O-methyl modified bases
on a phosphorothioate backbone, to anneal to the utrophin 3’UTR and prevent let-7c miRNA
binding, thereby upregulating utrophin expression and improving the dystrophic phenotype
in vivo. Suppression of utrophin: let-7c interaction using bi-weekly intraperitoneal injections
of let7 site blocking oligonucleotides (SBOs) for 1 month in the mdx mouse model for DMD,
led to increased utrophin expression along with improved muscle histology, decreased fibro-
sis and increased specific force. The functional improvement of dystrophic muscle achieved
using let7-SBOs suggests a novel utrophin upregulation-based therapeutic strategy for
DMD.
Introduction
Duchenne Muscular Dystrophy (DMD) is the most common fatal X-linked neuromuscular
disease. DMD is caused by mutations in the dystrophin gene that lead to quantitative and qual-
itative disturbances in the expression of the dystrophin protein [1–3]. Dystrophin is member
of the spectrin superfamily of proteins that includes the spectrins, alpha-actinins and utrophin
[4, 5]. Dystrophin provides structural integrity to muscle by linking the actin cytoskeleton to
the extracellular matrix via the muscle membrane bound dystrophin-glycoprotein complex
(DGC) [6, 7]. Lack of functional dystrophin disrupts this link, resulting in severe and progres-
sive muscle weakness and wasting. While great progress has been made in understanding the
etiology and pathogenesis of DMD, the disease remains incurable and is the focus of concerted
global efforts toward developing therapies [3, 8]. Utrophin is considered the autosomal
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homologue of dystrophin as it has extensive sequence similarity with dystrophin [9–12]. Func-
tionally, utrophin shares a number of important structural motifs with dystrophin, such as the
N-terminal, central spectrin repeat rod domain, cystine rich region and the C-terminal tail as
well as functional properties such as F-actin binding and ability to associate with the DGC [7,
9]. Utrophin is similar but not identical to dystrophin and differences such as nNOS [13] and
microtubule binding potential have also been reported [14]. Additionally, differences exist
both in the tissue and subcellular distribution [10, 15, 16]. Importantly from a therapeutic
point of view, multiple studies have demonstrated that utrophin upregulation using a variety
of different means (e.g. transgenic, viral vectors, pharmacological) can functionally rescue the
dystrophic phenotype in the mdx mouse model of DMD [17–21]. Additionally, even extremely
high levels of utrophin (e.g. using transgenic means) have not been associated with toxicity [3,
22], making utrophin upregulation an attractive therapeutic strategy for DMD. Indeed, a num-
ber of utrophin promoter trans-activator molecules have been identified and are in various
states of preclinical and clinical development [3, 18, 23, 24]. However, utrophin is also subject
to repression by several miRNAs including let-7c [25, 26]. Inhibiting the utrophin: let-7c inter-
action offers a potential method to upregulate utrophin expression for DMD gene therapy
[26].
To develop and test this strategy, we designed and used let-7 site blocking oligonucleotides
(SBOs) consisting of 2’-O-methyl modified bases on a phosphorothioate backbone that anneal
to the utrophin 3’UTR at the let-7 family target site and prevent utrophin translational repres-
sion by let-7c or other let-7 family members [26]. These oligonucleotides have a high affinity
for hybridization and do not induce RNase H-dependent cleavage [27]. They have been stud-
ied extensively in recent years as antisense therapeutic agents, which are protected against
extra- and intracellular degradation by their modified structure. Synthetic oligonucleotides are
being developed as therapies for a broad range of diseases, including hypertriglyceridemia
[28], viral infections [29] and to induce dystrophin exon skipping for DMD [30–33]. Since
let7-SBOs anneal to the utrophin 3’UTR, our blocking strategy is comparatively specific for
utrophin (Fig 1), rather than affecting other let-7 target genes [34–36] as would be the case in
using a let-7 miRNA sponge/antagomir strategy [37].
Materials and methods
Cell culture
The mouse muscle C2C12 myoblasts and human kidney HEK293T cell lines (both from
ATCC) were cultured in DMEM with 10% FBS, glutamine, penicillin and streptomycin.
Oligonucleotides
The let7-SBOs (5’-CUG AGG UAG AAA GGU GAU CAU GGC UC-3’) and control oligonucleo-
tides (5’-GUGAGC ACU UCU UUC CUU CUU UUU U-3’), are 20-O-methyl phosphorothioate
RNA oligos with a phosphorothioate backbone. The let7-SBOs was designed to specifically tar-
get the let7 miRNA binding site in the utrophin 3’UTR. These oligonucleotides were synthe-
sized on an Expedite 8909 Nucleic acid synthesizer using the 1 μmol thioate synthesis protocol
supplied by the manufacturer.
Constructs
For luciferase assays in stable cell lines, we used the previously described C2C12-5’3’ cell line
containing the 5’- and 3’-UTRs of utrophin flanking the luciferase coding sequence and stably
expressed in mouse C2C12 cells [38].
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For luciferase assays in human HEK293T cells, we generated the pGL4:50–50Luc30Hu con-
struct by amplifying the 50- (forward 5’-gtccaagcctGTATTGATGTCAAGCTGAACCA-3’
and reverse 5’-acttaagcctCTTGCCAGAGTTTCAAGATAATC-3’primers) and 30-UTRs
(forward 5’-caggggccggccAGTATTCATCCGGCCAACC-3’and reverse 5’-caaaggcc
ggccGTGTTAAAATTACTTTTATTCAGGATG-3’primers) of human utrophin and cloning
them into the Hind III and Fse I sites that flank the luciferase coding sequence in the pGL4:50
vector (Promega, Madison, WI).
For transient transfections in mouse C2C12 cells, we used the previously described pGL3-
50Luc30 construct containing the mouse 50- and 30-UTRs of utrophin flanking the luciferase
site [26]. The Q5 Site-Directed Mutagenesis Kit (New England Biolabs) was used for deleting
the let-7 site (24 bp sequence 5’-AGCCATGATCACCTTTCTACCTCA-3’; deletion of bases
from 3’UTR of utrophin (Accession number: NM_007124.2) from pGL3-50Luc30 to create the
pGL3-50Luc30-Δlet7 construct.
Fig 1. Therapeutic strategy for utrophin upregulation. Schematic representation for let-7 miRNA mediated repression of utrophin in
muscle and therapeutic strategy for utrophin upregulation by let7-SBOs. In left panel, the 3’UTR of utrophin-A contains a let-7 binding site
that is targeted by the let-7 miRNA, associated with a RNA-induced silencing complex (RISC) leading to translational repression and
decreased levels of utrophin protein. Right Panel shows let7-SBOs block the endogenous let-7 binding site of 3’UTR, preventing miRNAs
from binding. In this case, the normally occurring miRNA-mediated repression of utrophin will be repressed, leading to an increase in
utrophin expression.
https://doi.org/10.1371/journal.pone.0182676.g001
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Transfection
All oligonucleotide transfections were done using Lipofectamine RNAiMAX Transfection
Reagent (Invitrogen) according to the manufacturer’s instructions. For oligonucleotide trans-
fections, a 3: 1 ratio of Lipofectamine RNAiMAX (μl): μg oligonucleotides was used. For the
transfection of plasmid constructs we used the LF3000 Transfection Reagent (Invitrogen)
according to the manufacturer’s instructions.
Luciferase reporter assays
Cells (C2C12 or HEK293T) were plated in 24 well plates at 30,000 cells per well, 1 day before
transfection. 500 ng pGL3-5’Luc3’, pGL3-5’Luc3’-Δlet7 or equimolar amounts of other con-
structs were transfected, with 50 ng pRL-TK (Promega) and 100 nM let7-SBOs or control oli-
gonucleotides, per well. Reporter activity was measured using the Dual Luciferase Assay
(Promega) 24 hrs after transfection instructions using a TD 20/20 luminometer (Turner
Designs, Sunnyvale, CA).
Treatment of mdx mice with oligonucleotides and sample collection
Male mdx (C57BL/10ScSn-Dmdmdx/J) mice were obtained from The Jackson Laboratory (Bar
Harbor, ME, USA). Mice were housed at the animal facility at the University of Pennsylvania
before initiation of experiments. All experiments were approved by the Institutional Animal
Care and Use Committee at the University of Pennsylvania.
For an in vivo proof-of-principle, a single dose of 20 μg let7-SBOs and unrelated control oli-
gonucleotides was injected in tibialis anterior (TA) muscles of 1 month old male mdx mice
(n = 3 for each group).
For systemic in vivo study the block randomization method was used to randomize mice
into groups that result in equal sample sizes. Starting at an age of 1 month, mdx mice were
treated intraperitoneally with low (10 mg; n = 3) and high (100 mg; n = 3) of let7-SBOs per kg
body weight in 250 μl saline twice weekly for 1 month. For control 3 mdx mice in each group
were injected intraperitoneally with low (10 mg) and high (100 mg) of control oligonucleotides
per kg body weight in 250 μl saline twice weekly for 1 month.
Mice were sacrificed by carbon dioxide (CO2) euthanasia followed by cervical dislocation
after the final injection. Blood samples were taken by cardiac puncture under deep terminal
anesthesia for serum analysis. Serum was collected by centrifuging at 2,000 g for 5 min and it
was stored at -80˚C until analysis. After sacrifice, muscles and tissues were isolated, embedded
in OCT and frozen in liquid nitrogen-cooled Isopentane, and stored at -80˚C. Investigators
were not blinded for the study. For all experiments sample sizes (n) are indicated in each figure
legend.
Ex vivo physiological assessment of skeletal muscle
Physiological properties, including isometric twitch force, isometric tetanic force, and force
drop after ECCs, were quantified on freshly isolated EDL muscles from 2 months old mdx
mice using an Aurora Mouse 1200A System equipped with Dynamic Muscle Control v.5.3
software, as described previously [39, 40]. EDL muscles were maintained in constantly oxygen-
ated Ringer’s solution (100 mM NaCl, 4.7 mM KCl, 3.4 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM
MgSO4, 25 mM HEPES and 5.5 mM D-glucose) at 24˚C. The twitch stimulation protocol
applied was a single stimulus with a duration of 0.2 ms. For measuring tetanic maximal force
generation, the stimulus was repeated at a frequency of 120 Hz for 500 ms. Five min were
allowed between two tetanic contractions to ensure muscle recovery. Muscle length was
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adjusted to obtain the maximal twitch response and this length was measured and recorded as
optimal length (L0). Muscle cross-sectional area (CSA) of EDL muscles was calculated by
dividing the muscle mass by the product of the muscle density coefficient (1.06 g/cm3), muscle
L0, and the fiber length coefficient (0.45 for EDL). Specific force was determined by normaliz-
ing maximum isometric tetanic force to CSA.
After testing the isometric properties of EDL, a series of five ECCs was applied. The force
drop was calculated as the percent difference in tetanic force between the first and fifth ECC.
At the end of the physiological assessment, EDL muscles were embedded in OCT and frozen
in liquid nitrogen-cooled Isopentane, and stored at -80˚C.
Western blotting
Western blotting was performed as described [26]. Cells and mouse muscles were processed in
TNEC lysis buffer (1.5 mM Tris-HCl pH 8, 2.15 mM NaCl, 3.1% IGEPAL CA-630, 4.2 mM
EDTA with Complete Protease Inhibitors-Roche). Protein concentration was assayed using a
BCA Protein Assay Kit (Pierce). Approximately 30–40 μg protein were denatured with LDS
sample buffer and NuPAGE reducing reagent (both Invitrogen) and heated to 72˚C in for 10
min, then separated on 3–8% Tris-Acetate gels (Invitrogen) with Tris-Acetate running buffer
for 1.5 hrs at 100 V. Proteins were transferred to nitrocellulose membranes for 15 min at 25 V
in ice-cold transfer buffer (25 mM Tris-Cl pH 8.3, 192 mM glycine, 20% methanol, 0.05%
sodium dodecyl sulfate) using Trans-Blot Turbo transfer system (BioRad). Efficiency of trans-
fer and the even loading of lanes was verified by using post-transfer Ponceau-S staining of the
membrane. After digital scanning Ponceau-S staining was removed by TBST washing. Mem-
branes were blocked for 1 hr at room temperature in 5% non-fat milk in TBST (50 mM Tris-
Cl pH 7.5, 150 mM NaCl, 0.1% Tween 20), then probed for utrophin (upper half of mem-
brane) with mouse monoclonal anti-utrophin antibody MANCHO3 clone 8A4 (developed by
Glenn E. Morris and obtained from the Developmental Studies Hybridoma Bank, Iowa)
diluted 1:50 in 0.5% non-fat milk in TBST, or α-tubulin (lower half of membrane) with anti-α-
tubulin antibody clone DM1A (Sigma) or vinculin with anti-vinculin (7F9) mouse antibody
(Santa Cruz Biotechnology) diluted 1:2500 in 0.5% non-fat milk in TBST, for 1 hr at room
temperature. For probing c-Myc, Stat3 and Jak3 proteins anti-c-Myc Rabbit (D3N8F) mAb
(1:1000 dilution), anti-Stat3 (D3Z2G) Rabbit mAb (1:1000 dilution) and anti-Jak3 Rabbit mAb
(1:1000 dilution) were used in 0.5% non-fat milk in TBST, for 1 hr at room temperature. These
antibodies were obtained from Cell Signaling Technology, Inc. Membranes were washed in 3
changes of TBST for 5 min each, then incubated with HRP-conjugated goat-anti-mouse IgG
(Santa Cruz Biotechnology) or HRP-conjugated goat-anti-rabbit IgG (Santa Cruz Biotechnol-
ogy), diluted 1:2500 in 0.5% non-fat milk in TBST (for utrophin or α-tubulin), for 1 hr at
room temperature. TBST washes were repeated 3 times, then bands were visualized using
SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) and images
obtained using G:Box chemiluminescence system (Syngene). For presentation clarity, images
were then inverted to give dark bands on a light background. Band densities were quantified
using AlphaEaseFC (Alpha Innotech Corp.).
RNA isolation, reverse-transcription and quantitative real-time PCR
analysis
Trizol reagent (Life Technologies) was used for total RNA isolation from mouse tissues (e.g.,
diaphragm, gastrocnemius and TA). 1 μg total RNA was converted to cDNA using random
primers and SuperScript III First-Strand Synthesis System (Invitrogen). Quantitative PCR
(qPCR) was performed on QuantStudio3 Real-Time PCR System (Applied Biosystems) using
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Power SYBR Green Master Mix (Applied Biosystems) and primers 5’-GCGTGCAGTGGACCA
TTTTTCAGATTTA-3’and 5’-GCGTGCAGATCGAGCGTTTATCCATTTG-3’ for utrophin
or 5’-GGGCATCACCACGAAAATCTC-3’ and 5’-CTGCCGTTGTCAAACACCT-3’ for
RPLP0. Data was analyzed on QuantStudio Design & Analysis Software (Applied Biosystems).
Expression levels of Utrophin mRNAs were normalized to the endogenous control RPLP0
using ΔΔCt method.
Immunofluorescence analysis
Immunofluorescence staining of utrophin was performed on TA cryosections. Frozen sections
(10μm thick) were blocked for 1 hr in PBS containing 3% BSA and 0.05% Triton-X100, fol-
lowed by 1 hr incubation with specific primary antibody rabbit anti-utrophin polyclonal anti-
body (1:200) (C-19 sc-7459; Santa Cruz Biotechnology, Inc.) in PBS containing 2% goat
serum. After three PBS washes, sections were incubated for 1 hr with secondary antibody. For
secondary staining, goat Alexa-594 anti-rabbit (1:1000) (R37117; Molecular Probes, Inc.) with
α-Bungarotoxin (α-BTX), Alexa Fluor 488 conjugate (1:500) (B-13422; Molecular Probes,
Inc.) were used. Control tissue sections were processed simultaneously in the same manner.
Slides were rinsed three times for 5 min in PBS and mounted in ProLong Gold Antifade
Mountant (P36930; Molecular Probes, Inc.). The fluorescence digital images were acquired
using an Olympus BX51 microscope at an objective magnification of x20 and Olympus DP12
digital camera.
Muscle histology and morphology
Frozen muscle 10 μm sections were cut at the mid belly of TA and diaphragm. Sections were
fixed in ice-cold methanol for 5 min and then processed for histological examination by H&E
staining. The entire muscle section was imaged and analyzed. The single-fiber area distribu-
tions and total number of fibers were determined for each muscle from digital images acquired
using an Olympus BX51 microscope at an objective magnification of x10 and Olympus DP12
digital camera and software. Morphometric measurements (i.e., centrally nucleated fiber, sin-
gle-fiber minimal Feret’s diameter) were made using the ImageJ image-processing software
(rsbweb.nih.gov/ij). Minimal Feret’s diameter values for each muscle section were plotted as a
frequency histogram. Calculation of variance coefficients of the minimal Feret’s diameter was
calculated as described by Briguet et. al [41].
Serum CK quantification
Fresh, un-hemolysed serum was isolated from blood samples. Serum CK was measured with
the indirect colorimetric Creatine Kinase-SL Assay kit (Genzyme Diagnostics P.E.I. Inc., Char-
lottetown, Canada) according to the manufacturer’s instructions.
Hydroxyproline content
The content of the amino acid hydroxyproline has been used as a measure of the extent of
fibrosis in dystrophic skeletal muscle. Hydroxyproline assay was performed as described [42].
The TA muscle and the diaphragm were used for hydroxyproline quantification assay.
Statistical analysis
Data were analyzed using the GraphPad Prism v5 statistical software package (GraphPad Soft-
ware, La Jolla, CA). Data are reported as means ± SD. F-test was performed to test equality of
variance between populations / groups. For statistical significance Mann-Whitney U test, the
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Fig 2. Therapeutic strategy for utrophin upregulation validation in C2C12 cells. (A) Efficacy of
let7-SBOs in C2C12-5’Luc3’ utrophin reporter cells (cell line contains construct pGL4:50–5’Luc3’ where
reporter luciferase2 gene is flanked by the 5’- and 3’-UTRs of mouse utrophin-A). Cells transiently transfected
with let7-SBOs /control oligonucleotides and luciferase activity measured 24 hrs post-transfection. Results
shows significant increase in luciferase activity in C2C12-5’Luc3’ utrophin reporter cells 24 hrs of post-
Utrn ppregulation using let7-SBOs for DMD therapy
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2-way analysis of variance (ANOVA) with a Bonferroni correction or Tukey’s multiple com-
parison tests with statistical significance set at P 0.05 was performed. Appropriate statistical
tests have been mentioned in figure legends.
Results
To validate the blocking strategy, let7-SBOs was transiently transfected into mouse C2C12-
5’Luc3’ utrophin reporter cells, obtaining increased luciferase activity in a dose dependent
manner (Fig 2A). Increased endogenous utrophin expression was also noted in C2C12 cells
after let7-SBOs transfection at different concentrations (Fig 2B and 2C). The let7-SBOs treat-
ment in human HEK293T cells also showed increase in luciferase activity as well as utrophin
expression, demonstrating the applicability of this approach across species (S1 Fig). We also
validated the specificity of let7-SBOs and requirement of the let-7c site in the utrophin 3’UTR
for increasing utrophin expression. We developed a reporter construct (pGL3-5’Luc3’- Δlet7)
in which the let-7c binding site in the utrophin 3’UTR region was deleted using site directed
mutagenesis. Luciferase assays after 24 hrs of transient transfection of pGL3-5’Luc3’-Δlet7 con-
struct with control and let7-SBOs, in C2C12 cells showed no difference in luciferase activity
compared to upregulation noted using the pGL3-5’Luc3’ construct (S2 Fig). For an in vivo
proof-of-principle, a single dose of 20 μg let7-SBOs and unrelated control oligonucleotides
was injected in tibialis anterior (TA) muscles of 1 month old male mdx mice. After 1 month,
we observed c.a. 1.9-fold utrophin overexpression (S3 Fig).
To test the ability of let7-SBOs treatment to improve the dystrophic phenotype and obtain
proof-of-concept in vivo, 1 month old male mdx mice were injected bi-weekly with intraperito-
neal injection of let7-SBOs and control oligonucleotides at two different doses (low dose 10
mg/kg and high dose 100 mg/kg) for 1 month. After a month of treatment mice were sacrificed
and analyzed by morphological, biochemical and physiological means. We observed c.a. 1.4-
and 1.8-fold increase of utrophin expression in diaphragm (Fig 3A and 3B), 1.3 and 1.7-fold
increase in the gastrocnemius muscle (Fig 3C and 3D) and 2.1- and 3.2-fold increase in the TA
muscle (Fig 3E and 3F) of both low and high dose let7-SBOs treatment compared to control
oligonucleotides groups by western blot analysis. We also measured level of utrophin mRNA
expression in diaphragm, gastrocnemius and TA muscles (S4 Fig) and observed significant
increase in utrophin mRNA expression in diaphragm (c.a. 1.3-fold) and TA muscles (c.a.
2.5-fold) of high dose let7-SBOs treatment. Utrophin is enriched at the neuromuscular junc-
tion and myotendinous junction in adult skeletal muscle cells and extends the entire sarco-
lemma in developing and regenerating muscle [10, 16]. Immunofluorescence labeling for
utrophin showed c.a. 1.4 (low dose) and 1.5-fold (high dose) increased utrophin at both synap-
tic regions (S5 Fig) as well as in the extrasynaptic sarcolemma of fibers in the TA muscles of
let7-SBOs treated mdx mice compared to controls (Fig 4A and 4B). Morphologically, dystro-
phic muscles typically show a higher percentage of centrally nucleated fibers (CNF’s) [43, 44].
We observed significant reduction in the number of CNF’s in TA (c.a. 11% and 14%
transfection with let7-SBOs compared to control oligonucleotides at various concentrations. Bars represent
mean ± SD from 3 independent experiments. Statistical analysis was performed by 2-way ANOVA for multiple
comparison followed by Bonferroni correction (***P 0.001). (B) Endogenous utrophin protein expression in
C2C12 cells 24 hrs after transfection with let7-SBOs or control oligonucleotides at various concentrations,
assayed by western blotting. α-Tubulin staining was used to control for equal loading. (C) Quantification of
utrophin normalized to α-tubulin band density in western blot assay. Bars represent mean ± SD from 3
independent experiments and control. Control oligonucleotides treatment used as reference for utrophin
expression in each independent experiment. Statistical analysis was performed by 2-way ANOVA for multiple
comparison followed by Bonferroni correction (*P 0.05, ***P 0.001).
https://doi.org/10.1371/journal.pone.0182676.g002
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Fig 3. Effect of intraperitoneal let7-SBOs treatment on utrophin upregulation in muscles of 2 months old mdx mice after 1 month of
treatment. Western blots and quantification of utrophin expression in diaphragm (A, B), gastrocnemius (C, D) and TA (E, F) muscles with low and
high dose let7-SBOs treatment compared with control oligonucleotides. Vinculin was used to control for equal loading. Bands were densitometrically
evaluated, normalized to Vinculin. Bars represent mean ± SD (n = 3 per group). Differences between groups were analyzed by the Mann-Whitney U
test (*P 0.05).
https://doi.org/10.1371/journal.pone.0182676.g003
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reduction) and extensor digitorum longus (EDL) muscles (c.a. 9% and 7% reduction) in
the low and high dose let7-SBOs treated mice, compared to controls (Fig 5A and 5B). Morpho-
metric analyses of EDL muscles revealed a decrease in the variance coefficient of the minimal
Feret’s diameter in the low dose regimen (Fig 5C and 5D), indicating a decrease fiber heteroge-
neity and suggesting an improvement in dystrophic pathology [41]. Details of these measure-
ments and other morphometric parameters of measured are provided in Table 1. We next
examined whether the dystrophic histopathology was improved by let7-SBOs treatment.
Histological analysis showed a reduction in pathophysiological changes such as necrosis and
cellular infiltration in diaphragm (Fig 5E) and TA (Fig 5F) muscles from treated mdx mice
compared to controls in both low and high dose regimens. To determine whether the improve-
ment in morphology was associated with biochemical improvement, we analyzed the hydroxy-
proline content of muscles as a biochemical marker for fibrosis [45]. A significant reduction of
hydroxyproline was found in the diaphragm (Fig 5G) and TAs (Fig 5H) of mdx mice treated
with high dose of let7-SBOs compared to controls. No significant decrease in serum creatine
kinase (CK) was noted (S6 Fig). To quantify functional improvement, we analyzed physiologi-
cal properties of EDL muscle (Table 1). EDL muscles from high dose let7-SBOs treated mice
showed increased specific strength compared to controls (Table 1). No changes were noted in
post eccentric lengthening contraction (ECC) force drop (S7 Fig). Finally, we performed west-
ern assay for other let-7 target genes (e.g. c-Myc [34], Stat3 [35], Jak3 [36] etc.) to test our
blocking strategy is comparatively specific for utrophin, and we have not observed any change
in expression of these let-7 target genes (S8 Fig).
Fig 4. Utrophin expression in TA muscle of mdx mice treated with intraperitoneal injection of let7-SBOs. (A) Expression and localization of
utrophin in mdx mice treated with let7-SBOs. Frozen sections of the TA muscles immuno-labelled with anti-utrophin antibodies and α-BTX. Utrophin
labeling in regions of TA muscle with a paucity of neuromuscular junctions (demonstrated by lack of α-BTX staining). (Scale bar = 100 μm). (B) Relative
fluorescence quantification of utrophin expression in TA muscles with low and high dose let7-SBOs treatment compared with control oligonucleotides.
Frozen 10μm thick sections of the TA muscles immuno-labelled with utrophin antibodies. Bars represent mean ± SD (n = 3 mice per experimental group).
Statistical comparison was analyzed by Mann-Whitney U test (*P 0.05).
https://doi.org/10.1371/journal.pone.0182676.g004
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Discussion
miRNAs play an important role in the post-transcriptional control of utrophin expression.
Rosenberg et al, (2006) showed that the miR-206 targets Utrophin [25]. We had previously
found five additional miRNAs namely, let-7c, miR-150, miR-196b, miR-296-5p, miR-133b
could repress utrophin expression [26]. We chose let-7c as an appropriate initial candidate to
test our strategy since it is highly expressed in fast and slow skeletal muscles, and its antisense
Fig 5. Effect of intraperitoneal let7-SBOs treatment on muscles morphology. Regeneration was quantified from the central nucleation counted
from H&E-stained transverse TA (A) and EDL (B) muscles (n = 3 per group) sections from let7-SBOs treated mdx mice compared to the respective
dose of control oligonucleotides (Mann-Whitney U test, *P0.05). Scatter dot plot represent mean ± SD (n = 3 per group). (C, D) Histogram distribution
of EDL muscle fibers minimal Feret’s diameter in mdx mice (n = 3 per group) injected with low (C) and high (D) dose of let7-SBOs treated (red) and
control oligonucleotides (blue). Variance coefficient of minimal Feret’s diameter are shown in inset graph (variance coefficient 500±24 versus 431 ± 11
in low dose group and 489 ± 16 versus 444 ± 26 in high dose group). Statistical analysis was performed by Mann-Whitney U test (*P 0.05). Data
represent mean ± SD (n = 3 per group). (E, F) Representative images of H&E staining showing decreased muscle damage, lack of cellular infiltration
and fibrosis resulting from low and high dose of let7-SBOs treatment in diaphragm (E) and TA (F) compared to the respective dose of Control
oligonucleotides (Scale bar = 200 μm). (G, H) Muscles fibrosis analyzed by the hydroxyproline content of diaphragm (G) and TA (H) muscles from
let7-SBOs treated mdx showing hydroxyproline content in high dose of let7-SBOs treatment compared to the respective dose of control
oligonucleotides. Significant differences were assessed by Mann-Whitney U test (*P 0.05). Scatter dot plot represent mean ± SD (n = 3 per group).
https://doi.org/10.1371/journal.pone.0182676.g005
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inhibition in C2C12 cells caused a translational upregulation of the luciferase reporter [26]. By
utilizing let7-SBOs targeting 3’UTR instead of let-7c miRNA itself, biological functions of let-7
miRNA other than utrophin regulation, should remain unaffected, thus increasing specificity.
Our data presented in this study demonstrate a novel therapeutic strategy for DMD based on
inhibiting the utrophin:let-7c miRNA interaction using let7-SBOs. Systemic treatment of mdx
mice using let7-SBOs, led to utrophin upregulation and functional improvement of the dystro-
phic phenotype. While only two doses were used in this study, there was in general, a good cor-
relation between oligomer dose and response. The higher dose resulted in greater utrophin
expression and improvement compared to low dose treatment. However, even the high dose
treatment did not completely improve dystrophic changes; serum CK and susceptibility to
damage by ECCs were not improved. This might be related to initiating let7-SBOs treatment
at 1 month of age rather than in the prenatal period [46], an inadequate dosage, an inadequate
duration of treatment or an inherent limitation of the strategy itself. Additional modifications
or use of a different platform chemistry may increase the ultimate pharmacological effective-
ness of the let7-SBO approach such as has been noted with morpholinos (PMOs) [47]. Given
the variability to therapeutic response noted across different muscles as well as in short vs long
terms studies [48, 49], additional studies would be needed in different animal models to fully
determine the limitations of the present strategy. It is noteworthy that delivery of let7-SBOs by
simple intraperitoneal injections circumvents the need for using specialized viral vectors to
deliver genes and the potential problems with toxicity or immune response against the vector
or recombinant dystrophin molecule itself. Additionally, our approach could also be used in
combination with dystrophin or non-dystrophin-based therapies for DMD and may help
potentiate these approaches as well.
Supporting information
S1 Fig. Efficacy of let7-SBOs in human HEK293T cells. (A) HEK293 cells transiently trans-
fected with firefly luciferase reporter construct pGL4:50–5’Luc3’Hu (the reporter luciferase2
gene is flanked by the 5’- and 3’-UTRs of human utrophin-A) and let7-SBOs / control oligonu-
cleotides. Figure shows luciferase activity in HEK293T cells 24 hrs after transfection with let7-
Table 1. Comparison of morphological and physiological properties of EDL muscle.
10mg/kg dose 100mg/kg dose
Control oligonucleotides let7-SBOs Control oligonucleotides let7-SBOs
Weight (mg) 14.5 ± 1.0 (3) 14.5 ± 2.4 (3) 15.4 ± 0.5 (3) 12.2 ± 0.6** (3)
CSA (mm2) 2.5 ± 0.2 (3) 2.4 ± 0.4 (3) 2.5 ± 0.1 (3) 2.1 ± 0.1** (3)
Absolute force (mN) 352.5 ± 56.7 (3) 382.4 ± 81.6 (3) 395.5 ± 13.6 (3) 392.8 ± 17.3 (3)
Specific force (N cm-2) 14.0 ± 2.8 (3) 15.8 ± 2.2 (3) 15.8 ± 1.2 (3) 18.7 ± 0.6* (3)
ECC force decrease (1–5) (%) 36.3 ± 5.7 (3) 40.2 ± 0.4 (3) 51.5 ± 18.0 (3) 44.1 ± 10.7 (3)
ECC force drop (5th) (%) 63.7 ± 5.7 (3) 59.8 ± 0.4 (3) 48.5 ± 18.0 (3) 55.9 ± 10.7 (3)
Avg. of Minimal Feret’s diameter (μM) 32.01 ± 15.9 (1521) 32.24 ±13.8 (2046) 30.6 ± 15.4 (1174) 35.5 ± 16.2*** (1232)
Variance coefficient of Min. Feret’s diameter 499.5 ± 24.2 (3) 431.3 ± 11.4* (3) 489.4 ± 16.1 (3) 444.0 ± 26.1 (3)
Results are represented as mean ±SD; numbers in parentheses are n; asterisks, each dose of let7-SBOs treatment group compared with respective dose of
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SBOs compared to control oligonucleotides at various concentrations. Bars represent mean ±
SD from 3 independent experiments. Statistical analysis was performed by 2-way ANOVA for
multiple comparison followed by Bonferroni correction, P 0.01, P 0.001. (B) Endoge-
nous utrophin protein expression in HEK293T cells after 24 hrs of transient transfection with
let7-SBOs or control oligonucleotides at different concentrations was assayed by western blot-
ting. (C) Quantification of utrophin band density normalized to α-tubulin band density in
western blot assay. Bars represent mean ± SD from 3 independent experiments. Statistical anal-
ysis was performed by 2-way ANOVA for multiple comparison followed by Bonferroni correc-
tion (P 0.05, P 0.001).
(PDF)
S2 Fig. Luciferase activity of C2C12 cells transiently transfected with pGL3-5’Luc3’, pGL3-
5’Luc3’-Δlet7 construct and let7-SBOs. (A) Schematics of the WT reporter construct pGL3-
5’Luc3’ (luciferase reporter flanked by the 5’- and 3’-UTRs of mouse utrophin-A) and pGL3-
5’Luc3’-Δlet7 reporter construct (luciferase reporter flanked by the 5’- and 3’-UTRs of mouse
utrophin-A in which the let-7c binding site has been deleted) (B) C2C12 cells were transiently
transfected with pGL3-5’Luc3’ or pGL3-5’Luc3’-Δlet7 along with control oligonucleotides
(blue) or let7-SBOs (red). Figure shows luciferase activity measured after 24 hrs of transfection.
Bars represent mean ± SD from 4 independent experiments. Statistical analysis was performed
by 2-way ANOVA for multiple comparison followed by Bonferroni correction (P 0.01).
(PDF)
S3 Fig. Utrophin expression in TA muscle of mdx mice treated with intramuscular injec-
tion of let7-SBOs. (A) Utrophin expression in TA muscles of mdx mice (n = 3 per group) with
intramuscular injection of let7-SBOs and control oligonucleotides. α-Tubulin staining was
used to control for equal loading. (B) Quantification of utrophin normalized to α-tubulin
band density in western blot assay. Bars represent mean ± SD (n = 3 mice per experimental
group). Statistical comparison was analyzed by Mann-Whitney U test (P 0.05).
(PDF)
S4 Fig. Transcriptional expression of utrophin in mdx mice treated with intraperitoneal
injection of let7-SBOs. (A-C) Utrophin mRNA expression by RT-qPCR in diaphragm (A),
gastrocnemius (B) and TA (C) muscles of mdx mice (n = 3 per group) with intramuscular
injection of let7-SBOs and control oligonucleotides. RPLP0 was used as housekeeping gene.
Bars represent mean ± SD (n = 3 mice per experimental group). Statistical comparison was
analyzed by Mann-Whitney U test (P 0.05).
(PDF)
S5 Fig. Utrophin expression in TA muscle of mdx mice treated with intraperitoneal injec-
tion of let7-SBOs. Expression and localization of utrophin in mdx mice treated with let7-S-
BOs. Frozen sections of the TA muscles immuno-labelled with anti-utrophin antibodies and
α-BTX. Utrophin labeling in neuromuscular junction-rich regions (demonstrated by α-BTX
staining) of TA muscle (Scale bar = 100 μm).
(TIFF)
S6 Fig. Effect of let7-SBOs treatment in serum CK activity. Decrease in serum CK activity in
mdx mice treated with the low dose (A) and high dose (B) of let7-SBOs compared to control
oligonucleotides injected mdx mice. Scatter dot plot represent means ± SD (n = 3 in each
group). Statistical analysis was performed by Mann-Whitney U test (P 0.05) to low and
high dose treatment group, respectively.
(PDF)
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S7 Fig. Comparisons of drop in ECC force after five successive ECC’s of EDL muscles of
mdx mice. Force drop after five successive ECC’s in EDL muscles of mdx mice treated with
low (A) and high (B) dose of let7-SBOs and control oligonucleotides (n = 3 for each group).
Significant differences were assessed by 2-way ANOVA for multiple comparisons followed by
Bonferroni correction (P 0.05).
(PDF)
S8 Fig. Effect of let7-SBOs on other let7 target genes. Western blots and quantification of
other let-7 target genes c-Myc (A, B), Stat3 (C, D) and Jak3 (E, F) in gastrocnemius muscles
with low and high dose let7-SBOs treatment compared with control oligonucleotides. Vinculin
was used to control for equal loading. Bands were densitometrically evaluated, normalized to
Vinculin. Significant differences were assessed by Mann-Whitney U test (P 0.05). Bars rep-
resent mean ± SD (n = 3 per group).
(PDF)
S1 Table. Body and muscle weight of mdx mice.
(DOC)
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